查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1797990

2032 年表觀遺傳學診斷市場預測：按產品、技術、應用、最終用戶和地區進行的全球分析

Epigenetic Diagnostics Market Forecasts to 2032 - Global Analysis By Product (Reagents, Kits, Instruments, Enzymes and Services),Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球表觀遺傳學診斷市場預計在 2025 年達到 192 億美元，到 2032 年將達到 528 億美元，預測期內的複合年成長率為 15.5%。

表觀遺傳診斷利用表觀遺傳標記（例如DNA甲基化、組蛋白修飾和非編碼RNA表現）來檢測和監測疾病。與傳統的基因檢測不同，表觀遺傳診斷在不改變DNA序列的情況下評估基因表現的調控方式。這種方法可以更早、更準確地檢測出癌症、神經系統疾病和自體免疫疾病等疾病。此類診斷方法因其在個人化醫療、治療監測以及在分子層面上闡明疾病機制的潛力而日益受到重視。

根據美國癌症協會預測，2024年美國將新增201萬例癌症病例，約有611,720人死於癌症。

個人化醫療日益受到關注

個人化醫療日益受到關注，這是表觀遺傳診斷市場的主要驅動力。醫療保健提供者正轉向基於個人基因和表觀遺傳特徵的客製化治療策略。表觀遺傳診斷能夠更早、更準確地檢測疾病易感性，幫助臨床醫師制定個人化治療性介入。隨著以患者為中心的醫療成為主流，對能夠提供深入生物學洞察的分子診斷工具的需求持續成長，這使得表觀遺傳技術成為精準醫療革命的前沿。

表觀遺傳診斷高成本

表觀遺傳診斷程序的高成本是市場成長的主要限制因素。對先進定序技術、專用試劑和熟練人員的需求推高了營運成本。這些成本限制了其應用，尤其是在醫療預算有限的中低收入國家。此外，此類檢測的報銷範圍有限，限制了患者的可及性，延緩了其商業化進程，並阻礙了表觀遺傳診斷在各地區常規臨床實踐中的廣泛應用。

擴展到早期疾病檢測

表觀遺傳診斷在早期疾病檢測中有著巨大的應用機會，尤其是在腫瘤學和神經退化性疾病。這些工具可以在症狀出現之前檢測到基因表現的細微變化，以便及時介入。基於DNA甲基化模式的液態生物檢體等非侵入性檢測因其高靈敏度和特異性而備受關注。將臨床效用擴展到早期診斷，將為改善患者預後和降低長期治療成本帶來變革性的潛力。

資料隱私和道德問題

資料隱私和倫理問題對表觀遺傳學診斷的推廣應用構成重大威脅。敏感遺傳和表觀遺傳數據的收集和分析引發了關於知情同意、數據所有權以及潛在濫用的問題。未經授權存取或共用此類資訊可能導致就業和保險方面的歧視。這些擔憂促使人們呼籲建立更嚴格的法律規範和倫理框架。如果這些問題無法充分解決，可能會損害使用者的信任，並限制這些技術的大規模部署。

COVID-19的影響：

COVID-19 疫情為表觀遺傳診斷市場帶來了挑戰和機會。儘管許多地區已暫停非必要診斷檢測，但這場危機加速了分子檢測技術的創新和投資。關於 COVID-19 對錶觀遺傳標記影響的研究重新激發了人們對免疫和發炎路徑診斷的興趣。隨著醫療保健系統逐漸適應疫情後的現實，越來越多的人將包括表觀遺傳學在內的先進診斷技術納入常規實踐，以更好地監測疾病並進行風險分層。

試劑市場預計將成為預測期內最大的市場

試劑領域預計將在預測期內佔據最大的市場佔有率，這得益於其在檢測流程中的關鍵作用。試劑包括試劑套件、酵素、緩衝液、引子等，用於各種工作流程，例如DNA甲基化和染色質免疫沉澱。診斷檢測量的增加，加上學術和臨床領域研發的不斷加強，持續推動需求。試劑在手動和自動化平台上的持續使用，確保了其在整個預測期內保持穩定的市場主導地位。

DNA 甲基化部分預計將在預測期內實現最高複合年成長率

DNA甲基化領域預計將在預測期內實現最高成長率，這得益於其在癌症診斷、神經系統疾病和產前篩檢的廣泛應用。 DNA甲基化是研究最深入的表觀遺傳修飾之一，為基因調控和疾病進展提供了重要見解。甲基化特異性PCR和定序平台的技術進步提高了檢測準確性。不斷增加的研究資金和臨床檢驗的不斷深入，進一步推動了該領域在全球市場的快速擴張。

佔比最大的地區：

由於醫療基礎設施的不斷擴張、癌症發病率的上升以及基因組學投資的不斷增加，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、日本和印度等國越來越重視精準醫療和分子診斷。政府對生物技術研發的支持，以及人們對早期疾病檢測意識的不斷增強，正在推動該地區生物技術的應用。龐大的患者群也推動了臨床試驗活動和市場滲透。

複合年成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率，這得益於其先進的科研能力、雄厚的醫療資金以及精準醫療的早期應用。領先的生物技術公司和學術機構的存在將推動診斷平台的創新。支持性的法律規範和良好的患者意識將進一步加速臨床應用。隨著對非侵入性和個人化檢測的需求不斷成長，北美將繼續成為表觀遺傳學創新、臨床試驗擴展和商業化的熱點。

提供免費客製化：

訂閱此報告的用戶可獲得以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球表觀遺傳學診斷市場（按產品）

  • 試劑
  • 套件
    • ChIP定序套件
    • 亞硫酸氫鹽轉化試劑套件
    • RNA定序套件
    • 全基因組擴增試劑套件
  • 裝置
  • 酵素
  • 服務

6. 全球表觀遺傳學診斷市場（按技術）

  • DNA甲基化
  • 組蛋白甲基化
  • 微型RNA修飾
  • 染色質結構
  • 其他技術

7. 全球表觀遺傳學診斷市場（按應用）

  • 腫瘤學
    • 固態腫瘤
    • 液體腫瘤
  • 非腫瘤學
    • 發炎性疾病
    • 代謝疾病
    • 感染疾病
    • 心血管疾病
  • 其他用途

8. 全球表觀遺傳診斷市場（依最終用戶）

  • 學術研究
  • 臨床研究
  • 醫院和診所
  • 製藥和生物技術公司
  • 其他最終用戶

9. 全球表觀遺傳學診斷市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：主要發展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Illumina Inc.
  • Thermo Fisher Scientific
  • QIAGEN NV
  • Merck KGaA（Merck Millipore）
  • Agilent Technologies
  • Bio-Rad Laboratories
  • Abcam PLC
  • PerkinElmer Inc.
  • Active Motif
  • Diagenode SA
  • New England Biolabs
  • Zymo Research Corporation
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GlaxoSmithKline plc
  • Eisai Co. Ltd.
  • Pfizer Inc.
  • Janssen Pharmaceuticals Inc.
Product Code: SMRC30360

According to Stratistics MRC, the Global Epigenetic Diagnostics Market is accounted for $19.2 billion in 2025 and is expected to reach $52.8 billion by 2032 growing at a CAGR of 15.5% during the forecast period. Epigenetic diagnostics involves the use of epigenetic markers-such as DNA methylation, histone modification, and non-coding RNA expression-to detect and monitor diseases. Unlike traditional genetic tests, epigenetic diagnostics assess how gene expression is regulated without altering the DNA sequence. This approach allows for earlier and more precise detection of conditions like cancer, neurological disorders, and autoimmune diseases. These diagnostics are gaining momentum due to their potential in personalized medicine, treatment monitoring, and uncovering disease mechanisms at the molecular level.

According to the American Cancer Society, the estimated number of new cancer cases in the U.S. in 2024 was 2.01 million, with around 6,11,720 deaths caused by cancer.

Market Dynamics:

Driver:

Growing focus on personalized medicine

The increasing emphasis on personalized medicine is a key driver for the epigenetic diagnostics market. Healthcare providers are shifting toward tailored treatment strategies based on individual genetic and epigenetic profiles. Epigenetic diagnostics enable earlier and more accurate detection of disease predispositions, helping clinicians customize therapeutic interventions. As patient-centric care becomes mainstream, demand for molecular diagnostic tools that provide deep biological insights continues to rise, positioning epigenetic technologies at the forefront of the precision medicine revolution.

Restraint:

High cost of epigenetic diagnostic procedures

The high cost associated with epigenetic diagnostic procedures acts as a major restraint on market growth. Advanced sequencing technologies, specialized reagents, and the need for skilled personnel drive up operational expenses. These costs limit adoption, particularly in low- and middle-income countries where healthcare budgets are constrained. Furthermore, limited reimbursement coverage for such tests restricts patient access, slowing commercialization and impeding the broader integration of epigenetic diagnostics into routine clinical practice across diverse regions.

Opportunity:

Expansion into early disease detection

A significant opportunity lies in the application of epigenetic diagnostics for early disease detection, particularly in oncology and neurodegenerative disorders. These tools can detect subtle changes in gene expression before symptoms appear, allowing for timely intervention. Non-invasive tests such as liquid biopsies based on DNA methylation patterns are gaining attention for their high sensitivity and specificity. Expanding clinical utility into early-stage diagnosis offers a transformative potential for improving patient outcomes and reducing long-term treatment costs.

Threat:

Data privacy and ethical concerns

Data privacy and ethical concerns pose substantial threats to the adoption of epigenetic diagnostics. The collection and analysis of sensitive genetic and epigenetic data raise questions about consent, data ownership, and potential misuse. Unauthorized access or sharing of such information could lead to discrimination in employment or insurance. These concerns are prompting calls for stricter regulatory oversight and ethical frameworks, and unless adequately addressed, they may hinder user trust and limit large-scale deployment of these technologies.

Covid-19 Impact:

The COVID-19 pandemic created both challenges and opportunities for the epigenetic diagnostics market. While non-essential diagnostic testing was temporarily paused in many regions, the crisis also accelerated innovation and investment in molecular testing technologies. Research into COVID-19's impact on epigenetic markers sparked renewed interest in immune and inflammatory pathway diagnostics. As healthcare systems adapt to post-pandemic realities, there's growing momentum for integrating advanced diagnostics, including epigenetics, into routine care for better disease monitoring and risk stratification.

The reagents segment is expected to be the largest during the forecast period

The reagents segment is expected to account for the largest market share during the forecast period, owing to its critical role in enabling testing procedures. These include kits, enzymes, buffers, and primers used across various workflows like DNA methylation and chromatin immunoprecipitation. Rising volumes of diagnostic tests, coupled with increased R&D in academic and clinical settings, continue to boost demand. The consistent use of reagents in both manual and automated platforms ensures steady market dominance throughout the forecast period.

The DNA methylation segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the DNA methylation segment is predicted to witness the highest growth rate impelled by, its widespread application in cancer diagnostics, neurological disorders, and prenatal screening. As one of the most studied epigenetic modifications, DNA methylation provides critical insights into gene regulation and disease progression. Technological advancements in methylation-specific PCR and sequencing platforms have improved detection accuracy. Increased research funding and growing clinical validation are further propelling the segment's rapid expansion across global markets.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by expanding healthcare infrastructure, rising cancer incidence, and growing investments in genomics. Countries like China, Japan, and India are increasingly focusing on precision medicine and molecular diagnostics. Government support for biotechnology R&D, along with increased awareness about early disease detection, is spurring regional adoption. The availability of a large patient pool also enhances clinical trial activity and market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to, advanced research capabilities, strong healthcare funding, and early adoption of precision medicine. The presence of major biotechnology companies and academic institutions fosters innovation in diagnostic platforms. Supportive regulatory frameworks and high patient awareness further accelerate clinical implementation. As demand for non-invasive and personalized testing rises, North America remains a hotbed for epigenetics-based innovation, clinical trial expansion, and commercial

Key players in the market

Some of the key players in Epigenetic Diagnostics Market include Illumina Inc., Thermo Fisher Scientific, QIAGEN NV, Merck KGaA (Merck Millipore), Agilent Technologies, Bio-Rad Laboratories, Abcam PLC, PerkinElmer Inc., Active Motif, Diagenode SA, New England Biolabs, Zymo Research Corporation, F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Eisai Co. Ltd., Pfizer Inc. and Janssen Pharmaceuticals Inc.

Key Developments:

In June 2025, Illumina introduced its advanced epigenetic sequencing platform enabling high-throughput DNA methylation analysis with enhanced accuracy and speed. This system supports comprehensive epigenomic profiling for cancer and autoimmune diagnostics. Illumina expanded collaborations with leading academic and clinical research centers to accelerate biomarker discovery and clinical validation.

In May 2025, Thermo Fisher launched improved bisulfite conversion and methylation-specific PCR assay kits that simplify workflows for epigenetic biomarker analysis. The kits are designed for clinical labs and research institutions working on oncology and neurological disorders. Thermo Fisher also extended its global distribution network to increase accessibility.

In May 2025, QIAGEN launched automated DNA methylation analysis instruments and software in May 2025 aimed at clinical laboratories. The integrated solutions reduce hands-on time and improve reproducibility in epigenetic testing. QIAGEN engaged in partnerships with hospitals to integrate epigenetic diagnostics into personalized treatment pathways for cancer patients.

In April 2025, Merck expanded its epigenetics research product line in April 2025 with new antibodies and reagents targeting histone modifications. This expansion supports drug discovery and diagnostic research focused on epigenetic regulation mechanisms across multiple diseases.

Products Covered:

  • Reagents
  • Kits
  • Instruments
  • Enzymes
  • Services

Technologies Covered:

  • DNA Methylation
  • Histone Methylation
  • MicroRNA Modification
  • Chromatin Structures
  • Other Technologies

Applications Covered:

  • Oncology
  • Non-Oncology
  • Other Applications

End Users Covered:

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epigenetic Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents
  • 5.3 Kits
    • 5.3.1 ChIP Sequencing Kit
    • 5.3.2 Bisulfite Conversion Kit
    • 5.3.3 RNA Sequencing Kit
    • 5.3.4 Whole Genomic Amplification Kit
  • 5.4 Instruments
  • 5.5 Enzymes
  • 5.6 Services

6 Global Epigenetic Diagnostics Market, By Technology

  • 6.1 Introduction
  • 6.2 DNA Methylation
  • 6.3 Histone Methylation
  • 6.4 MicroRNA Modification
  • 6.5 Chromatin Structures
  • 6.6 Other Technologies

7 Global Epigenetic Diagnostics Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
    • 7.2.1 Solid Tumors
    • 7.2.2 Liquid Tumors
  • 7.3 Non-Oncology
    • 7.3.1 Inflammatory Diseases
    • 7.3.2 Metabolic Diseases
    • 7.3.3 Infectious Diseases
    • 7.3.4 Cardiovascular Diseases
  • 7.4 Other Applications

8 Global Epigenetic Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Academic Research
  • 8.3 Clinical Research
  • 8.4 Hospitals & Clinics
  • 8.5 Pharmaceutical & Biotechnology Companies
  • 8.6 Other End Users

9 Global Epigenetic Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina Inc.
  • 11.2 Thermo Fisher Scientific
  • 11.3 QIAGEN NV
  • 11.4 Merck KGaA (Merck Millipore)
  • 11.5 Agilent Technologies
  • 11.6 Bio-Rad Laboratories
  • 11.7 Abcam PLC
  • 11.8 PerkinElmer Inc.
  • 11.9 Active Motif
  • 11.10 Diagenode SA
  • 11.11 New England Biolabs
  • 11.12 Zymo Research Corporation
  • 11.13 F. Hoffmann-La Roche Ltd
  • 11.14 Novartis AG
  • 11.15 GlaxoSmithKline plc
  • 11.16 Eisai Co. Ltd.
  • 11.17 Pfizer Inc.
  • 11.18 Janssen Pharmaceuticals Inc.

List of Tables

  • Table 1 Global Epigenetic Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Epigenetic Diagnostics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Epigenetic Diagnostics Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 4 Global Epigenetic Diagnostics Market Outlook, By Kits (2024-2032) ($MN)
  • Table 5 Global Epigenetic Diagnostics Market Outlook, By ChIP Sequencing Kit (2024-2032) ($MN)
  • Table 6 Global Epigenetic Diagnostics Market Outlook, By Bisulfite Conversion Kit (2024-2032) ($MN)
  • Table 7 Global Epigenetic Diagnostics Market Outlook, By RNA Sequencing Kit (2024-2032) ($MN)
  • Table 8 Global Epigenetic Diagnostics Market Outlook, By Whole Genomic Amplification Kit (2024-2032) ($MN)
  • Table 9 Global Epigenetic Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 10 Global Epigenetic Diagnostics Market Outlook, By Enzymes (2024-2032) ($MN)
  • Table 11 Global Epigenetic Diagnostics Market Outlook, By Services (2024-2032) ($MN)
  • Table 12 Global Epigenetic Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 13 Global Epigenetic Diagnostics Market Outlook, By DNA Methylation (2024-2032) ($MN)
  • Table 14 Global Epigenetic Diagnostics Market Outlook, By Histone Methylation (2024-2032) ($MN)
  • Table 15 Global Epigenetic Diagnostics Market Outlook, By MicroRNA Modification (2024-2032) ($MN)
  • Table 16 Global Epigenetic Diagnostics Market Outlook, By Chromatin Structures (2024-2032) ($MN)
  • Table 17 Global Epigenetic Diagnostics Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 18 Global Epigenetic Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Epigenetic Diagnostics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Epigenetic Diagnostics Market Outlook, By Solid Tumors (2024-2032) ($MN)
  • Table 21 Global Epigenetic Diagnostics Market Outlook, By Liquid Tumors (2024-2032) ($MN)
  • Table 22 Global Epigenetic Diagnostics Market Outlook, By Non-Oncology (2024-2032) ($MN)
  • Table 23 Global Epigenetic Diagnostics Market Outlook, By Inflammatory Diseases (2024-2032) ($MN)
  • Table 24 Global Epigenetic Diagnostics Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
  • Table 25 Global Epigenetic Diagnostics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 26 Global Epigenetic Diagnostics Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 27 Global Epigenetic Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 28 Global Epigenetic Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global Epigenetic Diagnostics Market Outlook, By Academic Research (2024-2032) ($MN)
  • Table 30 Global Epigenetic Diagnostics Market Outlook, By Clinical Research (2024-2032) ($MN)
  • Table 31 Global Epigenetic Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Epigenetic Diagnostics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 33 Global Epigenetic Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.